N-acetylglutamate synthase (NAGS) deficiency is an ultra-rare metabolic disorder of the urea cycle, inherited in an autosomal recessive manner, caused by biallelic pathogenic variants in the NAGS gene. The lack of N-acetylglutamate prevents proper activation of carbamoyl-phosphate synthetase I (CPS1), leading to potentially life-threatening hyperammonemia, especially in the neonatal period.
N-acetylglutamate synthase deficiency
The NAGS gene encodes the mitochondrial enzyme N-acetylglutamate synthase, responsible for producing N-acetylglutamate (NAG) from glutamate and acetyl-CoA. NAG is the essential activator of carbamoyl-phosphate synthetase I (CPS1), the enzyme that initiates the urea cycle. This cycle is the main pathway for transforming ammonia, a toxic product of protein metabolism, into urea that can be eliminated in urine.
When NAGS activity is reduced or absent, CPS1 is not activated correctly, and the urea cycle becomes blocked, with rapid accumulation of ammonia in the blood. The biochemical pattern may resemble that of CPS1 deficiency, making genetic confirmation important. The disease is inherited in an autosomal recessive manner and can present as a severe neonatal form or as partial, later-onset forms triggered by infections, fasting, surgery, or excess protein.
Symptoms
The neonatal form usually appears in the first days of life, after initiating protein feeding. Symptoms derive from acute hyperammonemia and include feeding refusal, vomiting, progressive lethargy, hypotonia, respiratory distress, seizures, and encephalopathy. Without urgent treatment, it can rapidly progress to coma, irreversible brain damage, or death. Partial forms can present at any age with intermittent episodes of vomiting, irritability, confusion, ataxia, headache, seizures, or behavioral disturbances.
Disease management
Prevention is based on avoiding and immediately treating hyperammonemia episodes. In an acute crisis, protein intake is temporarily suspended, intravenous caloric support, nitrogen-scavenging drugs are administered, and, if necessary, hemodialysis. The specific treatment is N-carbamylglutamate or carglumic acid, an NAG analogue that activates CPS1 and can restore the urea cycle flow. In the long term, a protein-restricted diet, biochemical monitoring, action protocols for illness, and avoidance of prolonged fasting are recommended.
Genes analyzed
Bibliography
Al Kaabi EH, El-Hattab AW. N-acetylglutamate synthase deficiency: Novel mutation associated with neonatal presentation and literature review of molecular and phenotypic spectra. Mol Genet Metab Rep. 2016 Aug 17;8:94-8.
Kenneson A, Singh RH. Presentation and management of N-acetylglutamate synthase deficiency: a review of the literature. Orphanet J Rare Dis. 2020 Oct 9;15(1):279.
Simpson KL, MacLeod EL, Kakajiwala A, et al. Urea Cycle Disorders Overview. 2003 Apr 29 [updated 2025 Jul 3]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.
